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 ABSTRACT  
Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic 
(R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US. 
Methods: We constructed a cohort-based partitioned survival model for three health states 
(progression-free, progressed disease, and death). Using overall survival and progression-
free survival data from the nivolumab and investigator’s choice (IC) arms of the CheckMate 
141 study, the proportion of patients in each health state was estimated by parametric 
modeling over a 25-year period. Cost, utility, adverse event, and disease management data 
inputs were obtained from relevant literature and applied to patients in each health state. A 
scenario analysis was conducted assuming increased uptake of subsequent 
immunotherapies. A one-way deterministic sensitivity analysis assessed the impact of 
variation in multiple parameters. A probabilistic sensitivity analysis in which probabilistic 
distributions were applied to each input during 1,000 model iterations was also conducted. 
Results: Total costs incurred were higher with nivolumab ($101,552) than with IC ($38,067). 
Nivolumab was associated with a higher number of life-years (LY; 1.21) and quality-adjusted 
life-years (QALYs; 0.89), compared with IC (0.68 and 0.42, respectively). The incremental 
cost-effectiveness ratio for nivolumab compared with IC was $134,438 per QALY, and this 
remained qualitatively similar when increased uptake of subsequent immunotherapies was 
assumed ($129,603 per QALY). Sensitivity analyses supported these findings. 
Conclusion: These results suggest that, at a willingness-to-pay threshold of $150,000 per 
QALY, nivolumab is a cost-effective option for therapy of SCCHN in the US. 
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 INTRODUCTION 
Head and neck cancers (inclusive of neoplasms of the oral cavity, pharynx, larynx, sinuses, 
and salivary gland) are major causes of cancer-related mortality in the US, with 
approximately 65,410 new cases and 14,620 deaths annually1; an estimated 90% of all cases 
are squamous cell carcinoma of the head and neck (SCCHN)2. The economic burden of 
recurrent/metastatic (R/M) SCCHN in the US is considerable, with estimated 6-month 
attributable costs of $20,000–60,000 per patient3. Approximately three-quarters of patients 
diagnosed with SCCHN present with locoregionally advanced disease4; despite curative 
treatment (generally with chemoradiotherapy and/or surgery), a substantial proportion of 
these patients will experience recurrence, progression or metastases. 
 
In patients with R/M SCCHN, the addition of cetuximab to platinum-based chemotherapy in 
combination with fluorouracil (5-FU) as first-line therapy improves survival5, and until 
recently this regimen remained the standard of care first-line therapy in this setting6,7. More 
recently, programmed death receptor-1 (PD-1) antibodies such as pembrolizumab and 
nivolumab have been investigated in this clinical setting. These immune checkpoint 
inhibitors inhibit the programmed cell death 1 ligand (PD-L1)-mediated evasion of T-cell 
cytotoxicity exhibited by many tumor types8. The US Food and Drug Administration (FDA) 
recently approved pembrolizumab for first-line therapy of R/M SCCHN, either as 
monotherapy (in patients whose tumors express PD-L1), or in combination with platinum-
based chemotherapy and 5-FU9, based on observations of efficacy and safety from the 
KEYNOTE-048 trial10. 
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 In the second-line setting, pembrolizumab and nivolumab have demonstrated clinical 
efficacy and safety as therapy for SCCHN11,12. The randomized, open-label, phase III 
CheckMate 141 trial compared nivolumab with investigator’s choice (IC; methotrexate, 
docetaxel, or cetuximab) in patients with R/M SCCHN who had progressed after platinum-
based chemotherapy, and reported that patients receiving nivolumab had a significantly 
longer overall survival (OS) (7.5 months) compared with those receiving IC (5.1 months), and 
1-year survival was higher in the nivolumab group (36% vs 17%)12. Based on these findings, 
in November 2016 the FDA approved nivolumab for the treatment of R/M SCCHN with 
disease progression on or after platinum-based therapy13. 
 
Given the high costs of these novel therapies14, rigorous cost-effectiveness analysis is crucial 
for payers to optimize healthcare spending. A recent cost-effectiveness analysis from a US 
healthcare system perspective assessed nivolumab for R/M SCCHN compared with other 
approved therapies (methotrexate, docetaxel, or cetuximab) and reported that nivolumab 
was cost-effective above a willingness-to-pay (WTP) threshold of $150,00015; as only 15-
month of published outcomes data were available at that time, the analysis used a time 
horizon of only 3 years. Guidance from the National Institute for Health and Care Excellence 
(NICE) recommends that cost-effectiveness evaluations should consider a “lifetime horizon” 
for patients16. Longer-term outcomes data have now been reported for CheckMate 14117 , 
and the 2-year survival rate of 17% in patients receiving nivolumab suggests that a 3-year 
time horizon may underestimate the value of nivolumab treatment over a longer period. 
Another analysis using a 30-year time horizon reported that nivolumab had an ICER of 
$294,400 compared with IC18. Although that analysis used disease transition probabilities 
from CheckMate 141, corresponding utility values for progression-free (PF) and progressed 
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 disease (PD) were unavailable at that time and were instead derived from two different 
non-immunotherapy trials, with identical utilities applied to both the nivolumab and IC 
arms. Treatment-specific utility values from CheckMate 141 are now available for nivolumab 
and IC, and more accurately reflect the outcomes associated with each treatment. We 
assessed the incremental cost-utility of nivolumab for therapy of R/M SCCHN with disease 
progression on or after platinum-based therapy from a US healthcare system perspective, 
compared with the CheckMate 141 IC arm. 
 
METHODS 
Design and structure 
A cohort-based partitioned survival model was developed consisting of three mutually 
exclusive health states, representing the relevant primary stages of disease in R/M SCCHN: 
PF, PD, and death (Figure 1). All patients were assumed to be PF at the start of the analysis. 
The proportion of patients in each health state was estimated by parametric modeling of OS 
and progression-free survival (PFS) data from the nivolumab and IC arms of CheckMate 141. 
Consistent with the design of CheckMate 141, the three individual agents comprising the IC 
arm were considered as an aggregate unit.  
 
The process for fitting parametric survival curves to patient-level data was based on 
methodological guidance from the NICE Decision Support Unit, which advises that, if 
possible, the same parametric survival model should be selected when fitting independent 
parametric models to two arms for comparison when the proportional hazards assumption 
is not valid, as was the case for OS and PFS from CheckMate 14116. Akaike and Bayesian 
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 Information Criterion goodness-of-fit statistics were used to identify the best-fitting survival 
models.  
 
Model inputs  
Incidence of adverse events (AEs) with nivolumab and IC were calculated using CheckMate 
141 data reporting any grade 3, 4, or 5 AEs (i.e., AEs defined as severe, life-
threatening/disabling, or causing death, respectively, according to “Common Terminology 
for Adverse Events v5.0”)19 with an incidence of at least 5% in the nivolumab and IC arms20 
(Supplementary Table 1). Treatment-specific utilities for PF and PD health states were 
generated by applying a US population preference-weighting algorithm21 to 3-level EuroQol 
5-dimension health questionnaire (EQ-5D-3L)22 data collected in CheckMate 141 (Bristol-
Myers Squibb, data on file; OR NIVO 094, 2017) (Supplementary Table 2).  As AEs were 
expected to occur within the first treatment cycle, disutility of AEs was applied to the PF 
health state, based on values obtained by systematic literature review (Supplementary 
Table 3).  
 
Cost input parameters applied to the model included those related to drug acquisition and 
administration, monitoring, disease management, treatment of AEs, and subsequent 
treatments (Supplementary Table 4–9). When a patient was assumed to have died, an end-
of-life care cost of $10,528.07 was applied (based on reported costs for renal cell carcinoma, 
as no published SCCHN-specific costs were identified)23. Cost data for IC used in this analysis 
represented a mean of the individual agents used in the IC arm of CheckMate 141.  
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 The base case analysis assumed that all treatments were administered until disease 
progression, in line with their respective FDA-approved prescribing information. The base 
case analysis also assumed that 0.6% of patients receiving IC would subsequently receive 
immunotherapy (based on observations from CheckMate 141). An annual discount rate of 
3% was applied to all costs and outcomes. 
 
Outcomes 
Health state (PF, PD or death) occupancy was evaluated at 4-week intervals over the 
hypothetical 25-year duration of the model. Total healthcare costs and health outcomes 
were calculated by combining the cost, medical resource use, and utilities (EQ-5D-3L) 
assigned to each health state (PF and PD). Health outcomes included life-years (LYs) and 
quality-adjusted life-years (QALYs). Total costs represented the sum of costs for disease 
management, treatment acquisition, treatment monitoring, treatment of AEs, and 
subsequent treatments, and are reported in 2017 US$ per patient.  
 
Scenario and sensitivity analyses 
To better reflect evolving clinical practice and increasing use of immunotherapies, a 
“scenario analysis” was conducted assuming that 30% of patients receiving IC would 
subsequently receive immunotherapy. As it is possible that the disutilities associated with 
AEs may partly drive the lower utilities observed with IC treatment compared with 
nivolumab, a second scenario analysis removed the disutilities associated with AEs from the 
model, to account for the possibility of AE disutilities being double-counted during IC 
therapy. One-way deterministic sensitivity analyses (DSA) were conducted assessing 
variation in the multiple parameters. Individual parameters used in the base case scenario 
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 were replaced with estimated low (minimum) and high (maximum) values for sensitivity 
analyses; the range used was based on ± standard error for utility values, and ± 20% for all 
other inputs. To evaluate the impact of uncertainty on the estimated cost-effectiveness, a 
probabilistic sensitivity analysis (PSA) was conducted using probabilistic distribution of input 
values during 1,000 model iterations. PSA input values were estimated from multivariate 
normal distribution (for OS and PFS), gamma distribution (for disease management costs, 
acquisition costs, administration costs, monitoring costs, AE costs, other costs, and disutility 
of AEs), and beta distribution (for utility weights).   
 
RESULTS  
After preliminary evaluation of OS and PFS data from CheckMate 141, neither met the 
assumption of proportional hazards. The most appropriate models were log normal (for OS) 
and generalized gamma (for PFS); these were therefore selected for use in the base case 
analysis.  Parametric extrapolation of OS in patients receiving nivolumab was externally 
validated against 5-year survival data from the squamous non-small cell lung cancer cohort 
from the phase 1b, open-label CheckMate 003 study and found to be reliable 
(Supplementary Table 10). 
 
Base case analysis 
Total costs incurred with nivolumab ($101,552) and IC ($38,067) were largely driven by 
treatment acquisition costs ($75,981 and $14,599, respectively) and disease management 
costs ($20,816 and $16,316, respectively) (Table 1). Nivolumab was associated with a higher 
number of QALYs (0.89) and LY (1.21), compared with IC (0.42 and 0.68, respectively). 
Incremental cost-effectiveness ratios (ICERs) indicated that the cost per additional QALY 
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 with nivolumab was $134,438 compared with IC in the base case scenario (Table 2). The 
ICER for life-years gained with nivolumab was $118,455 per life-year. When the probability 
of patients receiving immunotherapies (nivolumab or pembrolizumab) in subsequent lines 
of therapy was increased in the IC arm (to reflect improved access to these treatments after 
their approval), total costs for IC increased. Consequently, the ICER for nivolumab versus IC 
decreased slightly, but all ICERs remained qualitatively similar to the base case (i.e., the ICER 
for nivolumab was $129,603 per QALY and $114,194 per life-year, compared with IC). An 
additional scenario analysis in which AE-related disutilities were removed from the model 
yielded a cost per QALY of $141,806, consistent with the base case findings. 
 
Deterministic sensitivity analyses  
A tornado plot representing DSA for nivolumab compared with IC is presented as Figure 2. 
The ICER for nivolumab versus IC did not change substantially with variation in individual 
parameters. ICERs were generally influenced most strongly by variation in discount rate on 
outcomes and costs, and health state utility values for nivolumab. 
 
Probabilistic sensitivity analyses  
The results of the PSA for 1,000 model iterations are presented in Table 3. These results 
supported the findings from the base case analysis, with the ICER for nivolumab ($137,927) 
considered cost-effective compared with IC at a WTP threshold of $150,000. A scatter plot 
of individual model iterations during the PSA is presented in Supplementary Figure 1. At a 
WTP threshold of $150,000, 62.2% of PSA model iterations were deemed cost-effective; a 
cost-effectiveness acceptability curve describing this is presented in Supplementary Figure 
2. 
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DISCUSSION  
 
The findings from the base case analysis in our model suggest that, at the $150,000 per 
QALY threshold generally considered acceptable in the US24, nivolumab would be cost-
effective compared with IC (consisting of methotrexate, docetaxel, or cetuximab). PSA 
results were similar to the base case analysis, and found that the majority (>60%) of model 
iterations estimated the ICER to be less than $150,000. One-way DSA demonstrated that 
variations in discount for costs and outcomes, and utility values for PD and PF, had the 
highest impact on resultant ICER estimates. When increased use of immunotherapies 
subsequent to IC therapy was assumed, in keeping with contemporaneous clinical 
observations, the incremental costs between nivolumab and IC decreased slightly. 
Consequently, the ICER for nivolumab was less than $130,000 per QALY versus IC in this 
scenario.  
 
Existing ICER thresholds continue to foment debate in the face of rising costs associated 
with novel therapies25, and vary greatly across countries in both their magnitude and the 
way they are applied26. The WTP threshold of $150,000 generally used in the US follows 
World Health Organization recommendations that the upper limit for cost-effectiveness of 
an intervention should be considered to be approximately three times gross domestic 
product per capita24. However, ICERs for oncology treatments are more than double those 
of non-oncology treatments27, and recent oncology-specific studies have suggested that the 
“true” threshold should be considered to be above $150,000: surveys from academic 
oncologists28 and observational analyses of patient behaviors29 suggest that a threshold as 
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 high as $250,000 may be acceptable, particularly in the metastatic setting. Given the 
spiraling costs of healthcare in the US, which are approximately double that of other high 
income countries per capita, optimization of healthcare resources is increasingly 
important.30 Initiatives such as the ASCO framework31 have attempted to provide objective 
guidance for assessing the cost-effectiveness of therapies but may not reflect affordability 
or additional “value” of treatments (such as novel mechanisms of action, providing 
treatment options when few are currently available, or therapies for rare or high-morbidity 
conditions)32,33. 
 
To the authors’ knowledge, two other analyses have used CheckMate 141 data to estimate 
the cost-effectiveness of nivolumab as therapy of R/M SCCHN from a US healthcare system 
perspective. Our findings broadly concur with those of Ward et al, who reported that 
nivolumab was cost-effective at a WTP threshold of $150,000 compared with IC15. However, 
our model extends over a more appropriate time horizon (25 years) and is therefore more 
likely to capture the “lifetime” perspective of patients receiving nivolumab in US clinical 
practice. A further economic analysis reported that nivolumab would not be cost-effective 
at currently accepted thresholds18. That study used a longer-term time horizon (30 years), 
but drew utility values from older, non-immunotherapy trials, and applied identical utility 
values for PF and PD to both nivolumab and IC arms. Both of these studies excluded the 
likelihood of subsequent therapy in patients with progressed disease after platinum-based 
therapy. Following the approval of immunotherapies, patients now have improved 
treatment options following disease progression.  
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 From a non-US approach, one analysis from the perspective of Canadian healthcare payers 
reported that the ICER for nivolumab compared with docetaxel was CAD $144,000, above 
the conventional WTP threshold of CAD $100,000 suggested by the authors34. However, by 
comparing nivolumab with docetaxel alone, these observations are unlikely to reflect US 
clinical practice. A further analysis from the perspective of the Swiss healthcare system 
assessed the cost-effectiveness of nivolumab compared with IC using a Markov model, and 
estimated that the ICER for nivolumab would be CHF 102,957, just above the authors’ 
proposed WTP threshold of CHF 100,00035. It should be noted that both of these analyses 
used a 5-year time horizon and are therefore unlikely to represent the “lifetime” 
perspective for patients with R/M SCCHN. Indeed, in the latter publication, a scenario 
analysis extending the time horizon to 10 years found nivolumab to be cost-effective, with 
an estimated ICER of CHF 93,32535. This illustrates the importance of considering the long-
term benefit of immunotherapies in cost-effectiveness analyses; clinical trials have shown 
such treatments to be associated with delayed responses and “responder” subpopulations, 
both of which require sufficient time horizons to become apparent36.  
 
There are several limitations to this analysis. The probabilities of patients experiencing AEs 
were based on clinical trial data for only grade 3 or above AEs and AEs occurring in more 
than 5% of patients. Consequently, the presence of rare or low-grade AEs with nivolumab 
may be underestimated in the model. However, the contribution of AE treatment to total 
costs was minimal, and DSA did not identify AE treatment as having a strong influence on 
the resultant ICERs. Disutility of AEs was not reported in the CheckMate 141 trial; the 
disutilities used in the present model have therefore been taken from other published 
literature (as listed in Supplementary Table 3). Lastly, it should be noted that WTP 
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 thresholds are variable and no clear consensus on their implementation or interpretation is 
presently available; caution should be taken when considering the results from this analysis. 
 
In conclusion, this analysis used survival models informed by data from the CheckMate 141 
clinical trial to compare the cost-effectiveness of nivolumab versus IC for therapy of R/M 
SCCHN. Despite higher treatment costs compared with standard care (IC), nivolumab is 
associated with a considerable improvement in QALYs and LY gained, and is a cost-effective 
option for therapy of R/M SCCHN in the US. 
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TABLES AND FIGURES  
Figure 1. Schematic representation of partitioned survival model and disease health state 
transitions. 
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 Figure 2. Deterministic sensitivity analysis of ICER response to variability of input 
parameters for nivolumab vs investigator’s choice arm. 
 
ICER: incremental cost-effectiveness ratio; OS: overall survival; PD: progressed disease; PF: 
progression-free. 
Range of input variability: ± standard error for utility values; ± 20% for all other inputs 
values. 
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 Table 1. Absolute value estimates of health outcomes and costs associated with each 
treatment in the model.  
AEs: adverse events; ICER: incremental cost-effectiveness ratio; LY: life-years; QALYs: 
quality-adjusted life-years. 
All costs are in 2017 US$. 
 
 
Table 2. Incremental gains with nivolumab vs investigator’s choice. 
 LYs QALYs Costs ($) Cost per LYG ($) Cost per QALY ($) 
Base case 0.54 0.47 63,485 118,455 134,438 
Assuming increased subsequent use of 
immunotherapies 
0.54 0.47 61,202 114,194 129,603 
Removing disutilities associated with AEs from the 
model 
0.54 0.45 63,482 118,455 141,806 
AEs: adverse events; FDA: US Food and Drug Administration; LY: life-years; LYG: life-years 
gained; QALYs: quality-adjusted life-years. 
All costs are in 2017 US$.  
 Health outcomes Costs ($) 
 
AE 
disutility 
LYs QALYs 
Disease 
manage
ment 
Treatment 
acquisition 
Treatment 
administr
ation 
Treatment 
monitoring 
AEs 
Subsequen
t 
treatment 
Total 
Nivolumab 
−0.04 1.21 0.89 20,816 75,981 1,661 275 1,977 842 101,552 
Investigator’s 
choice 
−0.07 0.68 0.42 16,316 14,599 2,057 72 3,800 1,222 38,067 
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 Table 3. Probabilistic sensitivity analysis of health outcomes and costs associated with 
each treatment in 1,000 model iterations. 
 
Total 
costs ($) 
Total 
QALYs 
Incremental 
costs ($) vs IC 
Incremental 
QALYs vs IC 
Incremental 
cost per QALY 
($) 
IC 37,743 0.421 – – – 
Nivolumab 102,974 0.894 65,231 0.473 137,927 
IC: Investigator’s choice; QALYs: quality-adjusted life-years.  
All costs are in 2017 US$. 
62.2% of model iterations had an incremental cost per QALY of less than $150,000. 
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 SUPPLEMENTARY MATERIAL 
Supplementary Figure 1. Scatter plot of incremental cost and QALY gains with nivolumab 
estimated during each of 1,000 model iterations generated during probabilistic sensitivity 
analysis 
 
QALY: quality-adjusted life-years.  
Deterministic gain with nivolumab: QALY, 0.47; costs, $63,485 
Probabilistic gain with nivolumab: QALY, 0.42; costs, $65,231 
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 Supplementary Figure 2. Cost-effectiveness acceptability curve of ICER versus probability 
of nivolumab being cost-effective versus IC 
 
IC: investigator’s choice; ICER: incremental cost-effectiveness ratio. 
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 Supplementary Table 1. Grade 3 or above all-cause adverse events included in the global 
base case economic model20. 
 Nivolumab Investigator’s choicea 
Anemia 5.9% 8.1% 
Aspartate elevation – – 
Cancer pain 0.4% – 
Decreased appetite – – 
Diarrhea 0.8% 2.7% 
Dyspnea 5.5% 1.8% 
Fatigue 3.4% 6.3% 
Febrile neutropenia – – 
Hyponatremia 4.7% 8.1% 
Hypothyroidism – – 
Leukopenia 0.4% 2.7% 
Malignant neoplasm 
progression 
18.6% 22.5% 
Mucositis – 1.8% 
Nausea 0.4% 0.9% 
Neutropenia – 7.2% 
Peripheral neuropathy – – 
Pneumonitis 1.3% – 
Rash – 0.9% 
Stomatitis 1.3% 8.1% 
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 Syncope 1.3% – 
aInvestigator’s choice consisted of cetuximab, docetaxel, or methotrexate.  
AE: adverse event. 
 
Supplementary Table 2. Health state utility estimates used in model. 
 Progression-free Progressed disease 
All patients 0.796 (95% CI: 0.761–1.0) 
[n = 470] 
0.729 (95% CI: 0.700–0.758) 
[n = 225] 
Nivolumab 0.805 (95% CI: 0.786–0.824) 
[n = 345] 
0.746 (95% CI: 0.716–0.775) 
[n = 172] 
Investigator’s 
choicea 
0.770 (95% CI: 0.708–0.833) 
[n = 125] 
0.676 (95% CI: 0.600–0.752) 
[n = 53] 
aInvestigator’s choice consisted of cetuximab, docetaxel, or methotrexate.  
Utility estimates were modeled using a US population preference-weighting algorithm21, 
applied to 3-level EuroQol 5-dimension health questionnaire data from CheckMate 141 
(Bristol-Myers Squibb, data on file; OR NIVO 094, 2017). 
CI: confidence interval 
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 Supplementary Table 3. Disutility associated with adverse events. 
Adverse event Disutility  Source 
Anemia −0.1250 Lloyd A, van Hanswijck de Jonge P, Doyle S, et al. Health state 
utility scores for cancer-related anaemia through societal and 
patient valuations. Value in Health 2008;11(7) 
Aspartate 
aminotransferase 
increase 
0.0000 Assumption 
Cancer pain −0.0690 Doyle S, Lloyd A, Walker M. Health state utility scores in 
advanced non-small cell lung cancer. Lung Cancer 2008;62: 
374-80 
Decreased 
appetite 
−0.0380 Hudgens S, Briggs A, Tremblay G, et al. Comparison of 
methods to estimate health state utilities in metastatic 
breast cancer (MBC). ISPOR 17th Annual European Congress, 
Amsterdam, The Netherlands, November 2014 
Diarrhea −0.0468 Nafees B, Stafford M, Gavriel S, et al. Health state utilities for 
non-small cell lung cancer. Health Qual Life Outcomes 
2008;6:84 
Dyspnea −0.2900 Grutters JP, Joore MA, Wiegman EM, et al. Treatment-related 
quality of life in patients surviving non-small cell lung cancer. 
Thorax 2010;65:903-07  
Fatigue −0.0735 Nafees B, Stafford M, Gavriel S, et al. Health state utilities for 
non-small cell lung cancer. Health Qual Life Outcomes 
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 2008;6:84 
Febrile 
neutropenia 
−0.0897 Assumed to be the same as neutropenia  
Hyponatremia −0.1910 Assumed to be the same as hypomagnesemia reflecting a 
24% decline in utility (from PF utility); Hannouf MB, Sehgal C, 
Cao JQ, et al. Cost-effectiveness of adding cetuximab to 
platinum-based chemotherapy for first-line treatment of 
recurrent or metastatic head and neck cancer. PLoS One 
2012;7:e38557 
Hypothyroidism 0.0000 Assumption 
Leukopenia −0.0897 Assumed to be the same as neutropenia 
Malignant 
neoplasm 
progression 
0.0000 Assumption 
Mucositis, oral −0.4410 Assumed to be the same as stomatitis 
Nausea −0.0480 Nafees B, Stafford M, Gavriel S, et al. Health state utilities for 
non-small cell lung cancer. Health Qual Life Outcomes 
2008;6:84 
Neutropenia −0.0897 Nafees B, Stafford M, Gavriel S, et al. Health state utilities for 
non-small cell lung cancer. Health Qual Life Outcomes 
2008;6:84 
Peripheral 
neuropathy 
0.0000 Assumption 
Ac
ce
pte
d M
an
us
cri
pt
 Pneumonitis −0.0080 Assumed to be the same as pneumonia; Marti SG, Colantonio 
L, Bardach A, et al. A cost-effectiveness analysis of a 10-
valent pneumococcal conjugate vaccine in children in six 
Latin American countries. Cost Eff Resour Alloc 2013;11:21 
Rash −0.0325 Nafees B, Stafford M, Gavriel S, et al. Health state utilities for 
non-small cell lung cancer. Health Qual Life Outcomes 
2008;6:84 
Stomatitis −0.4410 Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of 
systemic therapies for metastatic pancreatic cancer. Curr 
Oncol 2013;20:e90-e106 
Syncope 0 Assumption 
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 Supplementary Table 4. Drug acquisition costs used in the base case model. 
Treatment Formulation 
per vial/cap 
Vial size or 
tablets per 
pack 
Unit cost per vial 
or pack ($) 
Dose Total cost 
per dose, 
with vial 
sharing ($) 
Source 
Nivolumab 
10 mg/mL 10 mL 2,661.41 
3 mg/kg 6,387.38 
Medi-Span Price Rx
®
 
WAC price 10 mg/mL 4 mL 1,064.56 
Investigator’s choice       
Cetuximab 2 mg/mL 50 mL 621.70 250 mg/m
2
 
957.50 
Medi-Span Price Rx
®
 
WAC price 
Docetaxel 20 mg/mL 1 mL 25.00 30 mg/m
2
 
Methotrexate 1 g/ 40 mL 40 mL 325.13 40 mg/m
2
 
Subsequent treatments       
Cisplatin 
50 mg/50 
mL 
50 mL 17.00 100 mg/m
2
 NA 
Medi-Span Price Rx
®
 
WAC price 
Fluorouracil 100 g  217.70 9 mg/kg NA 
Medi-Span Price Rx
®
 
WAC price; bulk 
package, wastage 
not applicable 
NA: not applicable (for use without vial sharing); WAC: wholesale acquisition costs. 
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 Supplementary Table 5. Administration costs associated with infusion of treatments. 
Treatment Units per 4 
weeks 
Unit 
cost 
($) 
Source 
Nivolumab 2.00 
139.
61 
Nivolumab SPC and 2017 Centers for Medicare and 
Medicaid Service - Physician Fee Schedule. CPT 
code: 96413, Chemo IV infusion (1 hour) - Facility 
price, National Payment Amount 
Investigat
or’s choice 
 
 
 
Cetuximab 4 
139.
61 
2017 Centers for Medicare and Medicaid Service - 
Physician Fee Schedule. CPT code: 96413, Chemo 
IV infusion (1 hour) - Facility price, National 
Payment Amount 
Docetaxel 1.33 
Methotrex
ate 
4 
Subsequent treatments 
Cisplatin 1.33 
139.
61 
2017 Centers for Medicare and Medicaid Service - 
Physician Fee Schedule. CPT code: 96413, Chemo 
IV infusion (1 hour) - Facility price, National 
Payment Amount 
Fluorourac
il 
8 doses 
every 42 
days 
CPT: Common Procedure Terminology; IV: intravenous. 
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 Supplementary Table 6. Subsequent treatments used in base case model.  
 Nivolumab Investigator’s choice 
Proportion of patients receiving  
subsequent treatment (%) 
29.6 32.2 
Duration of treatment (months) 2.33 2.33 
Frequency of treatments (%)   
Nivolumab 0.7 0.6 
Cetuximab 7.7 6.1 
Docetaxel 3.4 2.4 
Methotrexate 5.7 4.3 
Paclitaxel 6.4 3.6 
Pembrolizumab 0.3 4.9 
Cisplatin (carboplatin / cisplatin) 4.0 5.5 
5-Fluorouracil 1.3 4.9 
Best supportive care 70.4 67.8 
Total cost of subsequent treatment  
per patient ($) 
2,948.28 3,867.60 
aInvestigator’s choice consisted of cetuximab, docetaxel, or methotrexate.  
Values based on CheckMate 141 observations (Bristol-Myers Squibb, data on file; OR NIVO 
174, 2019). 
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 Supplementary Table 7. Monitoring costs associated with nivolumab and investigator’s 
choice. 
 Test Units 
required per  
4 weeks 
Unit 
cost 
($) 
4-week 
cost ($) 
Source 
Nivolumab 
Hepatic 
enzymes 
1 11.21 
46.17 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
80076 
Renal function 1 11.91 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
80069 
Thyroid test 1 23.05 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
84443 
Investigator’s 
choicea 
Weighted average of individual costs 
for cetuximab, docetaxel and 
methotrexate 
19.64  
Cetuximab 
Complete 
metabolic 
panel 
1 14.49 14.49 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
80053 
Docetaxel CBC 1 10.66 10.66 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
85025 
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 Methotrexate 
CBC 1 10.66 
33.78 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
85025 
Hepatic 
enzymes 
1 11.21 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
80076 
Renal function 1 11.91 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
80069 
Subsequent therapies 
Cisplatin 
CBC 4 10.66 
53.85 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
85025 
Hepatic 
enzymes 
1 11.21 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
80076 
Fluorouracil CBC 
8 per 42 day 
cycle 
10.66 63.96 
2017 Medicare Laboratory 
Fee Schedule, CPT code 
85025 
aInvestigator’s choice consisted of cetuximab, docetaxel, or methotrexate.  
“Units required” based on respective label guidance. 
CBC: complete blood count; CMS: Center for Medicare and Medicaid Services; CPT: 
Common Procedure Terminology.  
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 Supplementary Table 8. Disease management costs for the progression-free and 
progressed disease health states. 
 Unit cost 
($) 
Units per  
4 weeksa 
Source for unit cost 
PF PD 
Office visit 79.67 4.1613 7.79 CMS – Physician Fee Schedule. CPT code: 
99214, National payment amount 
Fiber optic 
examination 
125.39 0.0022 0.0002 CMS – Physician Fee Schedule. CPT codes 
43191, 43193, 43197, 43198, 43200, 
43202, 43235, and 43239. Unweighted 
average of national payment amounts 
Magnetic 
resonance 
imaging 
781.80 0.002 0.0012 CMS – Physician Fee Schedule. CPT codes 
70511, 70553, 70540, 70543, and 70549. 
Unweighted average of national payment 
amounts 
Computerized 
tomography 
scan 
386.16 0.0588 0.0171 CMS – Physician Fee Schedule. CPT codes 
70486, 70487, 70450, 70470, 70490, 
70491, 71250, 70491, and 71275. 
Unweighted average of national payment 
amounts 
Positron 
emission 
tomography 
2,716.84 0.0329 0.0036 CMS – Physician Fee Schedule. CPT codes 
78811, 78812, 78813, 78814, 78815, and 
78816. Unweighted average of national 
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 payment amounts 
Percutaneous 
endoscopic 
gastrostomy 
210.02 0.0042 0.0091 CMS – Physician Fee Schedule. CPT codes 
49440, 49441, 49446, 49450, 49451, 
43246, 44372, 44373, 43653, and 43760. 
Unweighted average of national payment 
amounts (range: 48 to 594) 
Surgical 
procedure 
21,748.4
7 
0.0018 0.0012 HCUP NIS. Weighted average of DRGs 129 
and 130, Medicare costs 
Home health 
organization 
80.03 0.0414 0.0294 Assumption that home health care is 
speech and language therapy. CMS – 
Physician Fee Schedule. CPT codes 92507. 
National payment amounts 
Physical 
therapy/ 
rehabilitation 
31.77 0.0224 0.0034 CMS – Physician Fee Schedule. CPT codes 
97110 and 97140. Unweighted average of 
national payment amounts 
Orthopedic/ 
reconstruction/ 
ambulatory 
surgery 
21,748.4
7 
0.0075 0.0003 HCUP NIS. Weighted average of DRGs 129 
and 130, Medicare costs 
Psychiatry/ 
counseling/ 
psychology 
89.30 0.001 0.0046 CMS – Physician Fee Schedule. CPT codes 
90832, 90833, 90834, 90836, 90837, and 
90838. Unweighted average of national 
payment amounts) 
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 Dental specialist 79.67 0.001 0.0008 Assumption. CMS – Physician Fee 
Schedule. CPT code: 99214, National 
payment amount 
Pain 
management 
79.67 0.0002 0.0001 Assumption.  CMS – Physician Fee 
Schedule. CPT code: 99214, National 
payment amount 
Audiology 33.38 0 0 CMS – Physician Fee Schedule. CPT code: 
92557, National payment amount 
Optometry/ 
ophthalmology 
81.47 0 0 CMS – Physician Fee Schedule. CPT code: 
92014, National payment amount 
Total cost per 4 weeks: $652.81 $675.45  
CMS: Centers for Medicare and Medicaid Services; CPT: Common Procedure Terminology; 
CT: computed tomography; DRG: diagnosis related group; HCUP NIS: health care utilization 
project’s Nationwide Inpatient Sample; PD: progressed disease, PF: progression-free. 
aRates of resource use in PF and PD based on CheckMate 141 observations (Bristol-Myers 
Squibb, data on file; OR NIVO 055, 2017). 
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 Supplementary Table 9. Cost of adverse events.  
 Unit cost  (2014 $) Unit cost (2017 $) 
Anemia 7,066 7,689 
Aspartate  6,102 6,641 
Cancer pain 8,907 9,693 
Decreased appetite 14,010 15,246 
Diarrhea 7,041 7,662 
Dyspnea 6,058 6,593 
Fatigue 6,616 7,200 
Febrile neutropenia 11,480 12,493 
Hyponatremia 6,541 7,119 
Hypothyroidism 9,501 10,339 
Leukopenia 9,487 10,324 
Malignant neoplasm progression 0 0 
Mucositis 9,504 10,343 
Nausea 5,749 6,256 
Neutropenia 11,480 12,493 
Peripheral neuropathy 9,601 10,448 
Pneumonitis 13,329 14,506 
Rash 5,301 5,768 
Stomatitis 9,504 10,343 
Syncope 6,751 7,346 
Costs identified from the Healthcare Cost and Utilization Project Nationwide Inpatient 
Sample 201437, adjusted to 2017 values. 
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Supplementary Table 10. External validation of long-term parametric survival model using 
data from the phase 1b, open-label CheckMate 003 study. 
  Proportion of patients surviving at each timepoint (%) Median 
OS 
(months) 
Mean OS 
(months)   6 
months 
1 
year 
2 
years 
3 
years 
4 
years 
5 
years 
10 
years 
15 
years 
20 
years 
Base case Nivolumab 55.9 32.9 16.5 10.0 6.7 4.7 1.4 0.6 0.3 6.7 15.4 
 IC 46.9 19.2 5.7 2.3 1.1 0.6 0.1 0.0 0.0 5.1 8.2 
CheckMate 
141 
Nivolumab 56.5 34 15.8 N/A N/A N/A N/A N/A N/A 7.7 N/A 
 IC 43.0 19.7 N/A N/A N/A N/A N/A N/A N/A 5.1 N/A 
CheckMate 
003 
Nivolumab N/A 41 24 20 16 16 N/A N/A N/A N/A N/A 
IC: investigator’s choice; N/A: not applicable; OS: overall survival 
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